Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15619549 | 0.83 | CTRB1 (0.46) | CES1TSHRHPGDPOLB | |
| SCHEMBL7268813 | 0.78 | CES1 (0.44) | CES1FAAHTSHRSMN1; SMN2MEN1 | |
| SCHEMBL7283523 | 0.77 | TSHR (0.44) | CES1FAAHTSHRSMN1; SMN2MEN1 | |
| SCHEMBL14722636 | 0.75 | CHRM1 (0.39) | FAAHTSHR | |
| SCHEMBL11672054 | 0.71 | FAAH (0.44) | CES1FAAH | |
| SCHEMBL7319050 | 0.71 | ALDH1A1 (0.44) | CES1FAAHTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL108799 | 0.71 | DPP4 (0.49) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL2524872 | 0.71 | DPP4 (0.49) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6065210 | 0.71 | TAAR1 (0.50) | TSHRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL585398 | 0.70 | CYP1A2 (0.59) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| EP-2139836-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | The Royal Institution for the Advancement of Learning/McGill University (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122119-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | PLA2G1B, PLA2G4B, PLA2G2E | CES1 428/4885FAAH 26/4885TSHR 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.